Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2015)
✉ Email this page to a colleague
ASTRAZENECA PHARMACEUTICALS LP v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2015)
| Docket | ⤷ Start Trial | Date Filed | 2015-09-21 |
| Court | District Court, D. New Jersey | Date Terminated | 2015-12-08 |
| Cause | 35:271 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Karen M. Williams |
| Patents | 6,774,122; 7,456,160; 8,329,680; 8,466,139 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ASTRAZENECA PHARMACEUTICALS LP v. MYLAN PHARMACEUTICALS INC.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for ASTRAZENECA PHARMACEUTICALS LP v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-09-21 | External link to document | |||
| 2015-09-21 | 1 | THE PATENTS-IN-SUIT 23. United States Patent No. 6,774,122 (the “’122 Patent”), entitled…to the expiration of AstraZeneca’s U.S. Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139. … COUNT I: INFRINGEMENT OF U.S. PATENT NO. 6,774,122 37. Plaintiffs hereby reallege… U.S. PATENT NO. 6,774,122 48. Plaintiffs hereby reallege…. This is a civil action for patent infringement under the patent laws of the United States, Title | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
